---
schema_version: "secwatch.filing_event.v1"
accession: "0001104659-26-095491"
form_type: "8-K"
ticker: "MGTX"
cik: "0001735438"
company_name: "MeiraGTx Holdings plc"
filed_at: "2026-08-13T12:05:59+00:00"
generated_at: "2026-08-13T12:10:11.423008+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.9
calibrated_materiality_score: 0.9
confidence: "high"
source: SEC EDGAR
---

# MeiraGTx Q2 net income $160.7M; bota-vec acquired, $400M Oberland deal, BTD for AAV2-hAQP1

## Summary
- Q2 net income $160.7M ($1.76 basic EPS) vs net loss $38.8M in Q2 2025; revenue from services and licenses surged.
- Completed $25M acquisition of bota-vec (XLRP) from J&J; $100M equity financing; up to $400M Oberland investment with $375M non-dilutive.
- FDA granted Breakthrough Therapy Designation for AAV2-hAQP1; Phase 2 AQUAx2 enrollment completed; 3-year data positive.
- Lilly collaboration: $75M upfront, up to $400M milestones for medu-vec and gene therapy tech; also $95M due from Hologen.
- Cash $145.4M at June 30, 2026; expects runway into H2 2028.

## SEC filing metadata
- accession: 0001104659-26-095491
- form_type: 8-K
- ticker: MGTX
- cik: 0001735438
- company_name: MeiraGTx Holdings plc
- filed_at: 2026-08-13T12:05:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.9
- calibrated_materiality_score: 0.9
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1735438/000110465926095491/0001104659-26-095491-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1735438/000110465926095491/mgtx-20260813x8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001104659-26-095491
- JSON: https://secwatch.observer/filing/0001104659-26-095491.json
- Plain text: https://secwatch.observer/filing/0001104659-26-095491.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.